To relate how SMYD3/CP compares with other known factors regulating the response to chemotherapy in SCLC, we performed a similar analysis for EZH2 and SLFN11, which have been described to drive resistance to platinum-based agents in SCLC (35). This evidence concerns the gene EZH2 and small cell lung carcinoma.